Detecting meningiomas using non-contrast MRI techniques
MEningioma Detection Using Non Contrast MRI TecHniquEs
Fondation Ophtalmologique Adolphe de Rothschild · NCT04113408
This study is testing a new way to spot meningiomas, a type of brain tumor, using special MRI techniques that don't require contrast dye, making it safer for patients who need regular scans.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild (network) |
| Locations | 1 site (Paris) |
| Trial ID | NCT04113408 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the detection of meningiomas, a type of brain tumor, using non-contrast MRI techniques. The study aims to address the issues associated with gadolinium-based contrast agents, which can lead to harmful deposits in patients undergoing multiple MRI scans. By utilizing the FABIR sequence, the study seeks to provide a safer alternative for screening and monitoring meningiomas, particularly in patients at risk. Participants will be those undergoing MRI for known meningiomas, and their consent will be required for inclusion.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old who are undergoing MRI for screening or follow-up of known meningiomas.
Not a fit: Patients with contraindications for MRI, such as those with electrical devices or severe claustrophobia, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a safer method for monitoring meningiomas without the risks associated with gadolinium contrast agents.
How similar studies have performed: While the use of non-contrast MRI techniques is gaining interest, this specific approach using the FABIR sequence is relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient over 18 years of age * Patient performing MRI as part of a screening or follow-up of known meningioma * Express consent to participate in the study Exclusion Criteria: * Contraindication for MRI (electrical device, metallic foreign body, claustrophobia) * Known hypersensitivity to the contrast medium (Gadolinium) * Known renal failure: glomerular filtration rate \<30mL/min * Patient benefiting from a legal protection measure * Pregnant or breastfeeding woman
Where this trial is running
Paris
- Fondation ophtalmique Adolphe de Rothschild — Paris, France (RECRUITING)
Study contacts
- Study coordinator: Amélie YAVCHITZ, PhD
- Email: ayavchitz@for.paris
- Phone: 0148036454
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Meningioma